AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review-Reference-Cited by-同舟云学术

AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review

Published:2020-05 Issue:6 Volume:158 Page:1822-1830
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Loomba Rohit^ORCID,Lim Joseph K.,Patton Heather,El-Serag Hashem B.

Funder

National Institute of Environmental Health Sciences

National Center for Advancing Translational Sciences

National Institute of Diabetes and Digestive and Kidney Diseases

NIDDK

Cancer Prevention & Research Institute of Texas

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference79 articles.

1. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis;Loomba;Hepatology,2012

2. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study;Williams;Gastroenterology,2011

3. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease;Targher;N Engl J Med,2010

4. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

5. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis;Dulai;Hepatology,2017

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies;Metabolism;2024-12

2. Metabolic dysfunction-associated steatotic liver disease and its link to cancer;Metabolism;2024-11

3. DGAT2 Plays a Crucial Role to Control ESRRAPROX1 Transcriptional Network to Maintain Hepatic Mitochondrial Sustainability;Diabetes & Metabolism Journal;2024-09-30

4. Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma;Clinical Gastroenterology and Hepatology;2024-09

5. Lower hepatocellular carcinoma surveillance in metabolic dysfunction‐associated steatotic liver disease: Impact on treatment eligibility;Journal of Gastroenterology and Hepatology;2024-08-27